LONG-TERM EFFECTS OF ETANERCEPT TREATMENT ON VASCULAR FUNCTION AND LIPID PARAMETERS IN ANKYLOSING SPONDYLITIS

被引：0
|
作者：
Bodnar, N. [1 ]
Kerekes, G. [2 ]
Vegh, E. [1 ]
Gulyas, K. [1 ]
Balazs, F. [1 ]
Pogacsas, L. [1 ]
Pal, I. [1 ]
Szekanecz, Z. [1 ]
Szanto, S. [1 ]
机构：
[1] Univ Debrecen, Dept Rheumatol, H-4012 Debrecen, Hungary
[2] Univ Debrecen, Inst Med, H-4012 Debrecen, Hungary
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：958 / 958
页数：1
相关论文
共 50 条
  • [1] LONG-TERM EFFECTS OF ETANERCEPT AND CERTOLIZUMAB PEGOL TREATMENT ON VASCULAR FUNCTION AND LIPID PARAMETERS IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS
    Vegh, Edit
    Vancsa, Andrea
    Kerekes, Gyoergy
    Balazs, Fruzsina
    Pogacsas, Lilla
    Bodnar, Nora
    Szuecs, Gabriella
    Szanto, Sandor
    Szekanecz, Zoltan
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : A36 - A37
  • [2] LONG-TERM EFFECTS OF ETANERCEPT AND CERTOLIZUMAB PEGOL TREATMENT ON VASCULAR FUNCTION AND LIPID PARAMETERS IN RHEUMATOID ARTHRITIS
    Vegh, E.
    Kerekes, G.
    Vancsa, A.
    Balazs, F.
    Pogacsas, L.
    Pal, I.
    Szanto, S.
    Szuecs, G.
    Szekanecz, Z.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 411 - 411
  • [3] Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis
    Miguel Senabre-Gallego, Jose
    Santos-Ramirez, Carlos
    Santos-Soler, Gregorio
    Salas-Heredia, Esteban
    Sanchez-Barrioluengo, Mabel
    Barber, Xavier
    Rosas, Jose
    PATIENT PREFERENCE AND ADHERENCE, 2013, 7 : 961 - 972
  • [4] COMPARISON OF LONG-TERM DRUG SURVIVAL OUTCOME WITH ETANERCEPT TREATMENT AND ADALIMUMAB TREATMENT OF ANKYLOSING SPONDYLITIS
    Ruwaard, J.
    I'Ami, M.
    Marsman, A.
    Kneepkens, E.
    van der Horst-Bruinsma, I. E.
    van Denderen, C.
    Nurmohamed, M. T.
    Wolbink, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 813 - 813
  • [5] The effect of etanercept treatment on the lipid profile in patients with ankylosing spondylitis
    Huizer, E. E.
    van Eijk, I. C.
    Peters, M. J. L.
    de Koning, M. H.
    de Stadt, R. J. van
    van der Horst-Bruinsma, I. E.
    Dijkmans, B. A. C.
    Nurmohamed, M. T.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 398 - 399
  • [6] Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis
    Brandt, J
    Listing, J
    Haibel, H
    Sörensen, H
    Schwebig, A
    Rudwaleit, M
    Sieper, J
    Braun, J
    RHEUMATOLOGY, 2005, 44 (03) : 342 - 348
  • [7] Long-term efficacy, including halting of radiographicprogression, and safety of etanercept in patients with ankylosing spondylitis
    Dijkmans, B.
    Sridharan, S.
    Fatenejad, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 187 - 187
  • [8] Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice
    Arends, S.
    Brouwer, E.
    Efde, M.
    van der Veer, E.
    Bootsma, H.
    Wink, F.
    Spoorenberg, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (01) : 61 - 68
  • [9] Long-term efficacy and safety of infliximab treatment of ankylosing spondylitis
    Boeger, CA
    Wittwer, H
    Schattenkirchner, M
    Kellner, M
    JOURNAL OF RHEUMATOLOGY, 2001, 28 : 64 - 64
  • [10] Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis
    Elalouf, Ofir
    Elkayam, Ori
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 1719 - 1726
12345